The non-invasive detection of a mutant TERT promoter is especially attractive and has been evaluated in plasma, urine and cerebrospinal fluid (CSF) for the diagnosis/monitoring of HCC, bladder cancer and glioblastoma, respectively [31, 87–90]. This evidence concerns the gene TERT and urinary bladder cancer.